| Stationary Phase |
Mobile Phase |
Detection |
Linearity; LOD/LOQ |
Application |
Reference |
| C18 |
Methanol-0.04M ammonium acetate-acetonitrile (38:38:24v/v/v) +0.02% TEA (final pH 7.1) |
UV at 240 nm |
2.5-100 ng/ml |
Pharmacokinetic studies in rats |
28 |
| C18 |
Acetonitrile-methanol-pH 3.0, triethylamine solution (15:35:50 v/v/v) |
UV at 237 nm |
0.39-1.56 μg/ml;
LOD: 0.02 μg/ml
LOQ: 0.08 μg/ml |
Detection of amlodipine besylate residues in swab samples |
29 |
| C18 |
(A) 0.04M Ammonium acetate-methanol-acetonitrile (30:30:40v/v/v); (B) 1% acetic acid-methanol (1:1 v/v) |
(A) UV at 240nm;
(B) MS at 2 kV soft ionization with positive mode |
— |
— |
30 |
| C18 |
1% Triethylamine (pH3.0)-acetonitrile (65:35 v/v) |
UV at 220nm |
75-180 ppm
LOQ:21-35 ppm |
Quantification of alkyl benzene sulfonates in amlodipine besylate |
31 |
| C18 |
Acetonitrile and 0.05M sodium dihydrogen phosphate buffer
(60:40)pH 6 |
UV at 254 nm |
amlodipine besylate:
5-30 μg/ml and telmisartan:
10-60 μg/ml |
Pharmaceutical dosage form |
32 |
| C18 |
0.02M Potassium dihydrogen orthophosphate: acetonitrile (30:70 v/v)pH5 |
UV at 245 nm |
Telmisartan:
32-96μg/ml Amlodipin:
4-12μg/ml |
Tablet dosage form |
33 |
| C18 |
Buffer (0.7 % aqueous triethylamine pH 3 and methanol in the ratio of 40:60 (v/v) |
UV at 239 nm |
20-150 μg/ml |
Pharmaceutical dosage form(Oral Film) |
Present Research
work |
